Results 11 to 20 of about 1,210,671 (242)

Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy

Cancer Management and Research, 2017
Lingdong Shao,* Qingqin Peng,* Kaixin Du,* Junyan He, Yaping Dong, Xiaoyi Lin, Jinluan Li, Junxin Wu Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, People’s Republic of China *These ...
Shao LD, Peng QQ, Du KX, He JY, Dong YP, Lin XY, Li JL, Wu JX   +7 more
doaj   +1 more source

PD-L1-Expressing Extracellular Vesicles for the Treatment of Pneumonia

, 2023
Acute respiratory distress syndrome (ARDS) is a severe lung condition with a high mortality rate and a lack of effective drug therapy. In this work, we developed mesenchymal stem cell (MSC)-derived extracellular vesicles with high PD-L1 expression (MSC ...
Ting Lu (149031), Fang Xu (138747), Qingle Ma (10801724), Huaxing Dai (10801718), Heng Wang (76752), Yi Wu (197719), Chenlu Yao (17175038), Anning Song (17175035), Xiaoyu Wang (182979), Jialu Xu (8485347), Chao Wang (146527)   +10 more
core   +1 more source

PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect

, 2022
Immune checkpoint blockers (ICBs) targeting programmed death receptor 1 (PD-1) ligand 1 (PD-L1) for immunotherapy have radically reformed oncology. It is of great significance to enhance the response rate of ICB in cancer patients. Here, a radioiodinated
Yiren Zhang (1760983), Zhide Guo (1424674), Xueyuan Zeng (12728985), Jinxiong Huang (11276730), Xuejun Wen (349183), Xianzhong Zhang (1424671), Yesen Li (4430377), Haojun Chen (3727810), Jia Liu (41593), Xinying Zeng (6627383), Xingxing Cheng (4164958), Xiaoyuan Chen (322516)   +11 more
core   +1 more source

PD-1/PD-L1 blockade accelerates the progression of atherosclerosis in cancer patients

, 2022
PD-1(programed death-1)/PD-L1(programed death-1 ligand) blockade represents a major breakthrough of anti-cancer therapies, however, it may come with increased risk of cardiovascular morbidity, such as myocarditis, acute coronary syndrome, arrhythmias ...
Tse, Gary, Lin, Chen, Dong, Mei, Liu, Tong, Zhang, Nan, Lin, Zerun, Zhong, Lin, Yu, Ting, Wang, Rujian   +8 more
core   +1 more source

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo

EJNMMI Research, 2020
Background Preclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in the tumors.
Sheng Zhao, Wenbin Pan, Huijie Jiang, Rongjun Zhang, Hao Jiang, Zonghui Liang, Hongbo Hu   +6 more
doaj   +1 more source

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.

PLoS ONE, 2020
Programmed death-1 (PD-1) is an immunoinhibitory receptor expressed on lymphocytes. Interaction of PD-1 with its ligand PD-ligand 1 (PD-L1) delivers inhibitory signals and impairs proliferation, cytokine production, and cytotoxicity of T cells.
Otgontuya Ganbaatar, Satoru Konnai, Tomohiro Okagawa, Yutaro Nojima, Naoya Maekawa, Erina Minato, Atsushi Kobayashi, Ryo Ando, Nobuya Sasaki, Daisuke Miyakoshi, Osamu Ichii, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi   +14 more
doaj   +1 more source

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy

Cancer Medicine, 2020
Background Intravascular large B‐cell lymphoma (IVLBCL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) arising in extranodal sites. PD‐L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains ...
Yuka Suzuki, Kei Kohno, Kosei Matsue, Ayako Sakakibara, Eri Ishikawa, Satoko Shimada, Kazuyuki Shimada, Seiyo Mabuchi, Taishi Takahara, Seiichi Kato, Shigeo Nakamura, Akira Satou   +11 more
doaj   +1 more source

Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor

Bio-Protocol, 2023
Blockade of the programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) axis is a promising strategy for cancer immunotherapy. Although antibody-based PD-1/PD-L1 inhibitors have shown remarkable results in clinical cancer studies, their inherent ...
Tess Puopolo, huifang Li, Justin Gutkowski, Ang Cai, Navindra Seeram, Hang Ma, Chang Liu   +6 more
doaj   +1 more source

PD-L1 Expression in Mastocytosis [PDF]

International Journal of Molecular Sciences, 2019
Programmed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion. PD-L1 expression has been described as both a prognostic and predictive marker in many solid and hematologic neoplasms, as targeted therapies against
Margaret Williams, Diane S. Lidke, Karin Hartmann, Tracy I. George   +3 more
openaire   +4 more sources

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma [PDF]

Journal of Thoracic Disease, 2020
Thymoma is a relatively rare malignancy, which is categorized as thymic epithelial tumor but known as the most common pathology that is developed in the anterior mediastinum. Complete resection is recommended for localized tumors and usually favorable prognosis can be obtained.
Yokoyama, Shintaro, Miyoshi, Hiroaki
openaire   +2 more sources